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Inflammation is involved in the pathogenesis of heart fail-ure (HF).1,2 Although an inflammatory response is required 
for tissue repair after myocardial infarction,3 prolonged or 
excessive inflammation may be maladaptive, leading to myo-
cardial dysfunction and left ventricular (LV) remodeling.4 
Thus, although short-lived activation of interleukin-6 (IL-6) 
and related cytokines may be protective during ischemia, per-
sistent activation of these mediators may lead to the devel-
opment of cardiac hypertrophy and HF.5,6 In line with this, 
increased plasma IL-6 levels, proportional to disease severity, 
have been shown in patients with chronic HF of both ischemic 
and nonischemic causes, and high IL-6 concentrations have 
been associated with increased morbidity and mortality in 
these patients.5,7–9 Furthermore, 2 large genetic meta-analyses 
of >200 000 participants recently proposed a causative link 
between IL-6 signaling and coronary heart disease.10,11
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Within the myocardium, IL-6–type cytokines convey 
their signals predominantly through the signal transducer 
and activator of transcription 3 pathway via a glycoprotein 
130 (gp130) receptor subunit.5 The circulating levels of the 
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Background—Glycoprotein 130 (gp130) is the common signal-transducing receptor subunit of the interleukin-6 (IL-6) 
family, which may be involved in the progression of heart failure (HF). We hypothesized that soluble gp130 would provide 
prognostic information beyond that of IL-6 in a population with HF from the Controlled Rosuvastatin Multinational Trial 
in Heart Failure (CORONA).
Methods and Results—The associations of soluble gp130 and IL-6 with morbidity, mortality, and mode of death were 
assessed by immunoassays in a subset of 1452 patients enrolled in the CORONA trial, which included patients with 
HF, aged ≥60 years, in New York Heart Association classes II to IV, who had ischemic heart disease and a reduced left 
ventricular ejection fraction. In multivariable analyses, including C-reactive protein, IL-6, troponin T, and N-terminal 
pro-B-type natriuretic peptide, elevated soluble gp130 (fifth quintile versus all lower quintiles) was associated with 
all-cause mortality (hazard ratio, 1.47 [1.11–1.93]; P=0.006), cardiovascular mortality (hazard ratio, 1.38 [1.01–1.87]; 
P=0.042), and death from worsening HF (hazard ratio, 1.85 [1.09–3.14]; P=0.002), but not with the primary end point 
(composite of death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke; hazard ratio, 1.12 
[0.84–1.50]; P=0.44). Plasma IL-6 was not associated with outcomes in multivariable analyses.
Conclusions—Marked elevations in soluble gp130 are associated with total and cardiovascular mortality, as well as deaths 
from worsening HF, in elderly patients with HF of ischemic cause.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00206310. (Circ Heart Fail. 
2013;6:91-98.)
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common receptor subunit, soluble gp 130 (sgp130), could 
potentially reflect the activity of the whole IL-6 family, 
including myocardial activation. We, and others, have reported 
elevated sgp130 levels in patients with HF,7,12 but information 
on the prognostic relevance of sgp130 in HF is still limited.13 
In addition, comparisons of sgp130 and IL-6, as 2 markers of 
activity in the IL-6 cytokine family, for risk prediction in large 
HF cohorts are still lacking.
Accordingly, we investigated the association of sgp130 
and IL-6 with outcomes in a subset of patients enrolled in the 
Controlled Rosuvastatin Multinational Trial in Heart Failure 
(CORONA) trial, a large multicenter trial evaluating the 
effects of rosuvastatin in elderly patients with chronic, systolic 
HF of ischemic origin.
Methods
Patients and Study Procedures
The design and principal findings of CORONA have been reported in 
detail.14 Briefly, patients aged ≥60 years with chronic HF attributed to 
ischemic heart disease, defined as (1) medical history or ECG signs of 
myocardial infarction, or (2) other data suggesting an ischemic cause 
(eg, wall motion disturbances on echocardiography or history of other 
occlusive atherosclerotic disease [ie, earlier stroke, intermittent clau-
dication, percutaneous coronary intervention]), who were in New 
York Heart Association classes II to IV, with an LV ejection fraction 
≤40% (≤35% if New York Heart Association class II), were eligible 
for inclusion. The trial complied with the Declaration of Helsinki and 
was approved by the Ethics Committees of the participating hospi-
tals. All patients provided written informed consent. Patients were 
randomly assigned to rosuvastatin 10 mg/day or matching placebo, 
once-daily. The present study was an optional, predefined substudy of 
the main CORONA trial that included patients from centers capable 
of collecting the necessary blood samples. Baseline characteristics of 
the study population according to quintile values of sgp130 are shown 
in Table 1. Although in general similar to the main CORONA study, 
there were some modest but significant differences in the baseline 
characteristics between this substudy and the complete study popula-
tion (Table I in the online-only Data Supplement).
As a result of limited amounts of serum/plasma, measurement of 
all biomarkers in all patients was not always possible. A detailed 
overview of missing biomarker data are given in the Figure in the 
online-only Data Supplement.
Study Outcomes and Definitions
The primary predefined outcome was the composite of death from 
cardiovascular (CV) causes, nonfatal myocardial infarction, and non-
fatal stroke, analyzed as time to the first event. The secondary pre-
defined outcomes were (1) all-cause mortality, (2) CV mortality (with 
an additional analysis of cause-specific death from a CV cause), (3) 
any coronary event (ie, sudden death, fatal or nonfatal myocardial 
infarction, performance of percutaneous coronary intervention or cor-
onary artery bypass graft surgery, ventricular defibrillation by an im-
plantable cardioverter-defibrillator, resuscitation from cardiac arrest, 
or hospitalization for unstable angina pectoris), and (4) the number 
of hospitalizations for CV causes, unstable angina, and worsening of 
HF (WHF). Details on the definition and adjudication of all outcomes 
are described elsewhere, as are data on C-reactive protein (CRP) and 
N-terminal pro-B-type natriuretic peptide (NT-proBNP).14–17
Blood Sampling and Biochemical Analyses
Soluble gp130, IL-6, and troponin T (TnT) were measured from 
blood samples taken after an overnight fast. All other blood sam-
ples were nonfasting and analyzed on fresh samples at a central 
laboratory (Medical Research Laboratories, Zaventem, Belgium). 
NT-proBNP was analyzed using a commercially available assay 
(Roche Diagnostics, Basel, Switzerland). An immunonephelometric 
high-sensitivity method was used to measure CRP (Dade Behring, 
Atterbury, UK; sensitivity 0.04 mg/L). Plasma IL-6 was measured 
with a Randox multiplex cytokine high-sensitivity assay (Randox 
Laboratories Ltd, Crumlin, Co, Antrim, UK) with a detection limit 
of 0.4 pg/mL and inter- and intra-assay coefficient of variation of 
<20%. Seventeen patients had undetectable IL-6 levels. Serum TnT 
was analyzed with a high-sensitivity assay on a Roche Modular E170 
platform with a lower detection limit of 3 ng/L (Roche Diagnostics). 
Serum sgp130 was measured by enzyme immunoassay (R&D 
Systems, Minneapolis, MN). The detection limit of the assay was 
40 pg/mL, with interassay coefficient of variation of 5.9% and in-
tra-assay coefficient of variation for high (1:100 dilutions) and low 
levels (1:400 dilutions) of 7.8% and 9.4%, respectively. All patients 
had detectable sgp130 concentrations. Furthermore, sgp130 showed 
a median intraindividual (n=8) diurnal variation over 3 time points 
of 8.8% (P=0.37), with no difference between fasting and nonfasting 
sgp130 levels (P=0.57). When analyzing sgp130 in serum samples 
over 4-point dilutions from the upper limit of the assay, we found a 
mean coefficient of variation of 7% (SD 1.7), indicating no, or only 
minor, matrix effects.
Statistical Analysis
Soluble gp130 was initially evaluated as a log-transformed, continu-
ous variable and found to predict fatal outcomes, with no associa-
tions with the primary end point or hospitalizations (Table II in the 
online-only Data Supplement). A restricted cubic spline analysis with 
5 knots revealed nonlinearity of risk for all-cause mortality (signif-
icant end point for continuous sgp130 with the highest number of 
events), with a marked increase in poor outcome per unit increase 
in sgp130 for those patients with the highest sgp130 concentrations 
(Figure 1A). The turning point for the restricted cubic spline curve 
corresponded approximately to the transition between the fourth and 
the fifth quintile of sgp130. We subsequently dichotomized sgp130 
by the fifth versus the fourth lower quintiles in all further analyses. 
Plasma IL-6 displayed linearity of risk in the restricted cubic spline 
analysis and was included as a log-transformed, continuous variable 
in multivariable analyses.
Differences between the top quintile and the bottom 4 quintiles of 
sgp130 were tested with Student t test for normally distributed base-
line variables, Fisher exact test for categorical data, and Wilcoxon 
rank-sum test for non-normally distributed variables. Trends over 
sgp130 quintiles were tested with the Cuzick extension of the 
Wilcoxon rank-sum test, and all baseline variables with a P value 
for trend <0.05 were included in a multivariable analysis to identify 
degree of association with sgp130.
Survival analyses were conducted using the Cox proportional hazard 
regression model where sgp130 was included in a version of the 3-stage 
model described elsewhere,17 which included mainly clinical variables 
at step 1 (LV ejection fraction, New York Heart Association class, age, 
body mass index, diabetes mellitus, sex, intermittent claudication, and 
heart rate). At step 2, the estimated glomerular filtration rate and apo-
lipoprotein B/apolipoprotein A-1 ratio were included in the model. At 
stage 3, the log-transformed plasma concentrations of NT-proBNP, 
IL-6 and CRP were included, and, finally, at stage 4, the log-trans-
formed serum concentration of TnT was included. Harrell C-statistic 
was calculated for all end points using the multivariable model with 
and without sgp130, and the difference between the C-statistics was es-
timated. We calculated C-statistics both without (step 3) and with TnT 
values (step 4) (Table 2). To correct for overoptimism associated with 
validating a model in the same material from which it is developed, 
we implemented a jack-knife cross-validation approach, where predic-
tions for each observation were obtained from models developed on the 
remaining observations. These cross-validated probabilities were used 
to calculate jack-knife C-statistics. Recently, calculation of net reclas-
sification improvement (NRI) has been suggested for the evaluation of 
the prognostic usefulness of a biomarker.18 In particular, when no es-
tablished risk categories exist, the use of a category-free NRI has been 
advocated.19 We, therefore, calculated the category-free NRI after add-
ing sgp130 to the multivariable model at step 3 and step 4. Confidence 
intervals and P values for NRI were determined by boot-strapping with 
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Table 1. Baseline Patient Characteristics
Variable Total
sgp130 Quintiles
P, Trend P, Q5First Second Third Fourth Fifth
Sgp130 range, ng/mL 106.0–274.2 274.3–317.5 317.6–363.9 364.0–438.1 438.2–786.7
Age, y 71.8 (6.9) 71.5 (7.3) 71.9 (6.7) 71.7 (6.6) 72.3 (6.9) 71.5 (6.8) 0.810 0.378
Female sex 339 (23.3) 62 (21.3) 71 (24.5) 66 (22.7) 69 (23.8) 71 (24.5) 0.477 0.642
Smoking 175 (12.1) 33 (11.3) 37 (12.8) 38 (13.1) 25 (8.6) 42 (14.5) 0.684 0.159
NYHA Class 0.667 0.162
 II 468 (32.2) 99 (34.0) 81 (27.8) 88 (30.6) 115 (39.4) 85 (29.3)
 III 967 (66.6) 186 (63.9) 208 (71.5) 197 (68.4) 172 (58.9) 204 (70.3)
 IV 17 (1.2) 6 (2.1) 2 (0.7) 3 (1.0) 5 (1.7) 1 (0.3)
Ejection fraction, % 32 (7) 32 (7) 32 (6) 32 (7) 31 (7) 31 (7) 0.026 0.266
BMI, kg/m2 27.3 (4.6) 27.3 (4.5) 27.3 (4.4) 27.4 (4.7) 27.4 (4.3) 26.9 (5.0) 0.193 0.143
SBP, mm Hg 130 (16.0) 128 (15) 130 (16) 130 (16) 130 (17) 130 (16) 0.156 0.353
DBP, mm Hg 77 (9) 76 (9) 78 (9) 76 (8) 77 (10) 77 (9) 0.649 0.592
Heart rate, bpm 71 (11) 70 (10) 70 (10) 70 (10) 71 (11) 73 (12) 0.006 0.000
Medical history
 Hypertension 1013 (69.8) 183 (62.9) 213 (73.2) 201 (69.8) 206 (70.5) 210 (72.4) 0.054 0.284
 Diabetes mellitus 377 (26.0) 57 (19.6) 67 (23.0) 81 (28.1) 85 (29.1) 87 (30.0) 0.001 0.085
 Atrial fibrillation/flutter 318 (21.9) 51 (17.5) 62 (21.4) 55 (18.9) 64 (22.1) 86 (29.7) 0.001 0.001
 Myocardial infarction 916 (63.1) 172 (59.1) 169 (58.1) 199 (69.1) 189 (64.7) 187 (64.5) 0.052 0.634
 PCI or CABG 301 (20.7) 54 (18.6) 73 (25.1) 50 (17.4) 57 (19.5) 67 (23.1) 0.641 0.292
 Stroke 173 (11.9) 33 (11.3) 41 (14.1) 36 (12.5) 36 (12.3) 27 (9.3) 0.334 0.155
 Intermittent claudication 156 (10.7) 22 (7.6) 35 (12.0) 34 (11.8) 34 (11.6) 31 (10.7) 0.306 1.000
Laboratory measures
 Total cholesterol, mmol/L 5.23 (1.09) 5.27 (0.98) 5.38 (1.05) 5.29 (1.18) 5.14 (1.09) 5.07 (1.14) 0.001 0.006
 LDL, mmol/L 3.64 (0.97) 3.58 (0.91) 3.71 (0.88) 3.71 (1.10) 3.64 (1.01) 3.55 (0.95) 0.404 0.072
 HDL, mmol/L 1.23 (0.34) 1.22 (0.29) 1.25 (0.36) 1.23 (0.35) 1.23 (0.33) 1.24 (0.37) 0.890 0.603
 Triglycerides, mmol/L 2.01 (1.39) 2.07 (1.57) 1.91 (1.02) 1.95 (1.21) 2.02 (1.38) 2.10 (1.69) 0.632 0.212
 Apo B/Apo A-1 value 0.89 (0.25) 0.87 (0.24) 0.90 (0.26) 0.92 (0.29) 0.88 (0.23) 0.87 (0.24) 0.807 0.165
 eGFR
MDRD, mL/min per 1.73 m
2 57 (14) 59 (14) 58 (13) 58 (14) 55 (15) 57 (15) 0.016 0.744
 CRP, mg/L 3.7 (1.6–7.7) 3.8 (1.8–8.0) 3.4 (1.5–7.2) 3.6 (1.6–8.4) 4.4 (1.7–7.6) 3.4 (1.6–6.8) 0.710 0.294
 NT-proBNP, pmol/L 160 (59–341) 135 (53–302) 124 (49–258) 162 (66–333) 186(80–349) 217(73–494) <0.001 <0.001
 IL-6, pg/mL 3.0 (1.9–5.5) 2.8 (1.9–5.0) 2.9 (1.7–5.3) 2.8 (1.8–5.0) 3.0 (2.1–5.7) 3.2 (1.8–6.5) 0.034 0.113
 Troponin T, ng/L 13.9 (6.6–25.6) 11.4 (4.6–20.2)  11.5 (4.8–23.1)  13.5 (7.3–25.3)  16.5 (8.6–29.9)  16.3 (7.8–30.8) <0.001 <0.001
 sgp130, ng/mL 339 (286–417) 243 (221–260) 296 (286–307) 339 (329–352) 397 (381–417) 515 (474–587)
Medications
 Diuretics 0.003 0.121
  Thiazide or loop 1105 (76.1) 240 (82.5) 228 (78.4) 213 (74.0) 213 (72.9) 211 (72.8)
  Thiazide and loop 157 (10.8) 16 (5.5) 20 (6.9) 35 (12.2) 45 (15.4) 41 (14.1)
 Aldosterone antagonist 530 (36.5) 95 (32.6) 105 (36.1) 106 (36.8) 104 (35.6) 120 (41.4) 0.057 0.056
 ACE inhibitor 1168 (80.4) 224 (77.0) 238 (81.8) 238 (82.6) 238 (81.5) 230 (79.3) 0.549 0.620
 ARB 147 (10.1) 29 (10.0) 27 (9.3) 30 (10.4) 32 (11.0) 29 (10.0) 0.754 1.000
 β-Blocker 1108 (76.3) 213 (73.2) 225 (77.3) 223 (77.4) 231 (79.1) 216 (74.5) 0.578 0.440
 Digitalis glycoside 418 (28.8) 65 (22.3) 78 (26.8) 73 (25.3) 89 (30.5) 113 (39.0) <0.001 <0.001
Clinical and biochemical baseline characteristics stratified by quintile values of sgp130. CRP, NT-proBNP, IL-6, TnT, and sgp130 are displayed as median value 
(25th–75th percentiles). Other variables are shown as number (percentage of total) or as mean (SD) where appropriate. ACE indicates angiotensin-converting enzyme; 
ApoA-1, apolipoprotein A-1; ApoB, apolipoprotein B; ARB, angiotensin II receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CRP, C-reactive 
protein; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IL-6, interleukin 6; LDL, low-density lipoprotein; MDRD, 
modification of diet in renal disease; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; P, trend, probability value for trend 
across all quintiles; P, Q5, probability value for fifth quintile compared with all lower quintiles; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; 
sgp130, soluble glycoprotein 130; and TnT, troponin T.
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2000 repetitions. A 2-sided P<0.05 was considered to be significant, 
except for interaction terms, for which P<0.10 were accepted. All sta-
tistical analyses were performed using STATA version 11 for Windows 
(StataCorp, College Station, TX).
Results
Serum sgp130 was measured at baseline and at 3 months in 
1452 patients. Patients in the top quintile of sgp130 were 
more likely to be in atrial fibrillation, take digoxin, and had 
slightly higher heart rates (Table 1). They also had lower cho-
lesterol and higher NT-proBNP and TnT. In addition, patients 
in higher quintiles had more diabetes mellitus, slightly worse 
renal function, lower LV ejection fraction, and were more 
likely to be taking loop and thiazide diuretics in combina-
tion. In multivariable regression modeling, diabetes mellitus, 
digitalis use, use of loop and thiazide diuretics combined, and 
TnT remained associated with sgp130. TnT was the strongest 
determinant of sgp130, but explained only ≈2.5% of the varia-
tion in baseline sgp130 concentration.
IL-6 and sgp130 Levels and Association  
With Outcomes
During a median follow-up of 955 (25th–75th percentiles, 817–
1103) days, 411 patients reached a primary end point and 425 
patients died. Kaplan–Meier plots for all-cause and CV mortality 
revealed a markedly reduced survival for patients in sgp130 Q5 
compared with all lower quintiles combined (Figure 1B and 1C).
When adjusting for demographic and clinical variables (step 
1) in a 4-step multivariable analysis, sgp130 was associated 
with all-cause mortality, death because of CV causes, includ-
ing death from WHF, and hospitalization because of WHF. 
However, sgp130 was associated with neither the primary nor 
the coronary end point (Table 2). The inclusion of medica-
tions and extended medical history in an expanded Cox model 
did not alter these associations substantially (Table III in the 
online-only Data Supplement). The associations with mortal-
ity remained significant after adjusting for apolipoprotein B/
apolipoprotein A-1 ratio and estimated glomerular filtration 
rate (step 2). After correcting for NT-proBNP, IL-6 and CRP 
(step 3), and TnT (step 4) sgp130 remained a strong predic-
tor for overall mortality and death from CV causes, including 
death from WHF, with little change in hazard ratio from the 
unadjusted model (Table 2). Importantly, although related to 
sgp130, log-transformed, continuous IL-6 showed no associa-
tion with any of the end points after adjustment for CRP and 
NT-proBNP (Table IV in the online-only Data Supplement).
Although area under curve analyses revealed limited discrim-
inatory value of sgp130 alone (Table 3), addition of sgp130 in 
the multivariable analyses did not substantially alter effects of 
other variables (Table V in the online-only Data Supplement), 
suggesting incremental value of sgp130 and a noncompeting 
relationship to conventional risk factors and established bio-
markers. This finding is further underscored by highly signifi-
cant continuous NRIs for both all-cause (NRI 0.24; P<0.001) 
and CV mortality (NRI 0.22; P=0.006) when sgp130 was 
added to the multivariable models in step 3 (Figure 2 and Table 
2). However, when accounting for TnT (step 4), sgp130 did not 
enhance risk prediction for any end points (Table 2). Finally, 
sgp130 used as a continuous variable carried similar prognos-
tic information in models adjusted for clinical variables alone, 
but when adjusted for NT-proBNP, the association with CV 
death was of only borderline significance (P=0.06), and signif-
icance for all outcomes was lost after adjusting for TnT (Table 
II in the online-only Data Supplement).
Effect of Rosuvastatin Treatment on IL-6- and 
sgp130 Levels and Clinical Outcomes
Plasma IL-6 and serum sgp130 concentrations were similar 
at baseline and 3-month follow-up (continuous variable) both 
in patients assigned to placebo and rosuvastatin (P=0.99 and 
Figure 1. Restricted cubic spline analysis showed nonlinearity 
of risk for all-cause mortality, with increasing risk from approxi-
mately Q5 (A); fitted curve with 95% confidence interval. Kaplan–
Meier curves for all-cause (B) and cardiovascular (CV; C) mortality 
according to quintile sgp130 concentration. Q1 indicates lowest 
quintile serum sgp130; and Q5, highest quintile serum sgp130. 
Patients with the highest sgp130 levels (Q5) displayed mark-
edly reduced survival compared with all lower quintiles (Q1–4); 
P=0.0001 for all-cause mortality, P=0.0006 for CV mortality.
 by guest on July 20, 2017
http://circheartfailure.ahajournals.org/
D
ow
nloaded from
 
Askevold et al  Soluble gp130 in Chronic Heart Failure  95
Table 2. Multivariable Analyses: Effects of sgp130 on Outcomes
sgp130, Quintiles Events HR (95% CI) P Wald C Index, Δ* NRI
Primary end point
 Step 1† n=1449 411 1.19 (0.95–1.50) 0.137 2.21
 Step 2‡ n=1434 408 1.22 (0.97–1.54) 0.091 2.85
 Step 3§ n=1183 314 1.22 (0.93–1.59) 0.154 2.04 <−0.0001 (0.96) 0.14 (0.067)
 Step 4‖ n=1015 270 1.12 (0.84–1.50) 0.438 0.60 0.0007 (0.49) 0.04 (0.61)
All-cause mortality
 Step 1 425 1.40 (1.12–1.74) 0.003 9.06
 Step 2 422 1.43 (1.15–1.78) 0.001 10.20
 Step 3 322 1.54 (1.20–1.98) 0.001 11.20 0.0047 (0.15) 0.24 (<0.001)
 Step 4 275 1.47 (1.11–1.93) 0.006 7.42 −0.0043 (0.16) 0.16 (0.051)
Death from CV cause
 Step 1 346 1.38 (1.08–1.76) 0.009 6.76
 Step 2 344 1.41 (1.10–1.80) 0.006 7.60
 Step 3 263 1.47 (1.11–1.95) 0.007 7.17 0.0035 (0.25) 0.22 (0.006)
 Step 4 225 1.38 (1.01–1.87) 0.042 4.12 −0.0026 (0.33) 0.11 (0.19)
Death from WHF
 Step 1 102 1.98 (1.31–2.99) 0.001 10.40
 Step 2 102 2.00 (1.32–3.04) 0.001 10.50
 Step 3 78 2.25 (1.39–3.66) 0.001 10.80 0.0140 (0.11) 0.32 (0.090)
 Step 4 69 1.85 (1.09–3.14) 0.023 5.15 −0.0060 (0.47) 0.18 (0.39)
Sudden death
 Step 1 196 1.07 (0.75–1.51) 0.714 0.13
 Step 2 194 1.09 (0.77–1.55) 0.620 0.25
 Step 3 150 1.21 (0.82–1.79) 0.340 0.91 <−0.0001 (0.97) 0.19 (0.068)
 Step 4 129 1.25 (0.83–1.90) 0.286 1.14 <−0.0001 (0.99) 0.075 (0.42)
Coronary end point
 Step 1 332 1.00 (0.76–1.31) 0.984 <0.001
 Step 2 327 0.99 (0.75–1.30) 0.955 0.003
 Step 3 254 1.00 (0.73–1.36) 0.989 <0.001 −0.002 (<0.001) −0.09 (0.29)
 Step 4 212 0.95 (0.67–1.01) 0.759 0.094 0.0017 (0.025) −0.053 (0.35)
Hospitalization, CV causes
 Step 1 611 1.14 (0.94–1.39) 0.190 1.72
 Step 2 605 1.12 (0.92–1.37) 0.242 1.37
 Step 3 491 1.03 (0.82–1.28) 0.825 0.049 −0.001 (<0.001) <0.01 (0.92)
 Step 4 417 1.00 (0.79–1.28) 0.977 <0.001 0.0012 (<0.001) −0.013 (0.85)
Hospitalization from WHF
 Step 1 329 1.30 (1.01–1.68) 0.042 4.15
 Step 2 327 1.28 (0.99–1.66) 0.057 3.62
 Step 3 268 1.18 (0.89–1.58) 0.258 1.28 −0.0006 (0.64) 0.07 (0.36)
 Step 4 232 1.23 (0.91–1.68) 0.181 1.79 0.0007 (0.70) 0.05 (0.52)
Soluble gp130, dichotomized by fifth (Q5) versus all lower quintiles (Q1–4), as a predictor of outcome. All hazard ratios (HR) are given as HR (95% confidence 
interval). ApoA-1 indicates apolipoprotein A-1; ApoB, apolipoprotein B; C index, Δ, difference in C index between adjusted models with and without inclusion of sgp130, 
corresponding (P value); CRP, C-reactive protein; CV, cardiovascular; LVEF, left ventricular ejection fraction; NRI, net reclassification improvement calculated from C 
indexes for adjusted models with and without inclusion of sgp130, corresponding (P value); NYHA, New York Heart Association; and WHF, worsening heart failure.
*C index, Δ: difference in C index between adjusted models with and without inclusion of sgp130, corresponding P value.
The models are adjusted as follows: †Step 1: LVEF, NYHA functional class, age, body mass index, diabetes mellitus, sex, intermittent claudication and heart rate.
‡Step 2: All variables from step 1, as well as ApoB/Apo A-1 ratio and estimated glomerular filtration rate. 
§Step 3: All variables from step 2, as well as NT-proBNP, IL-6, and CRP.
‖Step 4: All variables from step, 3 as well as troponin T.
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0.36, respectively). No interaction was observed between 
neither IL-6 nor sgp130 and treatment group. Furthermore, 
sgp130 performed similarly in multivariable analyses in both 
the total (Table 2) and the placebo arm (Table VI in the online-
only Data Supplement) of the study population.
Discussion
In this post hoc analysis of CORONA, we found that serum 
concentrations of sgp130, but not IL-6, were associated with 
fatal outcomes in a large population of elderly patients with 
chronic systolic HF of ischemic origin.
We, and others, have demonstrated elevated levels of 
sgp130 in HF patients, with increasing levels according to 
disease severity.7,12,20 However, few patients (n<100 in each 
study) were included in these reports. Gwechenberger et al13 
also reported an association between sgp130 and WHF, inde-
pendently of NT-proBNP, in a small HF population of mixed 
cause. We now show, in a large population of HF patients with 
many events, that serum levels of sgp130 are associated with 
all-cause and CV mortality, including death from WHF, even 
after adjusting for NT-proBNP, CRP, IL-6, and TnT. To our 
knowledge, this is the first large-scale evaluation of the predic-
tive power of sgp130 in HF.
The ability to reflect several upstream pathogenic pathways 
is a desirable feature of a biomarker.21 The capacity of sgp130 
to mirror the activity of several IL-6–related cytokines, of 
which many have been implicated in the pathogenesis of 
HF,5,6 may account for its association with fatal outcomes 
in this analysis. In contrast to IL-6, sgp130 was associated 
with all fatal outcomes, except for sudden death, in the fully 
Figure 2. Net reclassification improvements (NRIs) 
of sgp130 on all-cause (A) and cardiovascular (CV; 
B) mortality at step 3; NRI 0.24, P<0.001 for all-
cause mortality and NRI 0.22, P=0.006 for CV mor-
tality. Ideally, all patients with events are reclassified 
upward (higher risk), and all patients without events 
are reclassified downward (lower risk). Green dots 
indicate improved risk estimation.
Table 3. Area Under Curve: sgp130 vs NT-proBNP
End Point sgp130, Q5 P NT-proBNP P IL-6 P
Primary end point 0.522 (0.501–0.543) 0.042 0.676 (0.646–0.707) <0.001 0.590 (0.561–0.617) <0.001
All-cause mortality 0.537 (0.516–0.559) 0.001 0.691 (0.662–0.720) <0.001 0.612 (0.584–0.641) <0.001
Death from CV causes 0.536 (0.513–0.560) 0.003 0.707 (0.675–0.739) <0.001 0.608 (0.577–0.640) <0.001
Death from WHF 0.576 (0.529–0.623) 0.002 0.753 (0.700–0.808) <0.001 0.661 (0.609–0.713) <0.001
Sudden death 0.511 (0.481–0.540) 0.475 0.688 (0.644–0.733) <0.001 0.574 (0.531–0.618) 0.001
Hospitalization for CV causes 0.518 (0.500–0.535) 0.040 0.617 (0.592–0.642) <0.001 0.566 (0.548–0.590) <0.001
Hospitalization for WHF 0.534 (0.510–0.558) 0.005 0.692 (0.661–0.723) <0.001 0.614 (0.584–0.645) <0.001
Coronary end point 0.504 (0.482–0.526) 0.729 0.643 (0.608–0.677) <0.001 0.561 (0.528–0.594) <0.001
AUC (95% CI) of sgp130 as a categorical (top quintile versus lower four quintiles) variable compared with AUC of NT-proBNP and IL-6 for all end points. AUC indicates 
area under curve; CI, confidence interval; CV, cardiovascular; IL-6, interleukin-6; NT-proBNP, N-terminal pro-B-type natriuretic peptide; sgp130, soluble glycoprotein 
130; and WHF, worsening heart failure.
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adjusted Cox model. This suggests that sgp130 might better 
reflect IL-6–type activity than IL-6 itself. From a practical 
point of view, IL-6 circulates at low levels (<10 pg/mL), often 
just above the detection limit of the assay, whereas sgp130 cir-
culates at high concentrations (>100 ng/mL), making it more 
suitable as a clinical biomarker.
Soluble gp130 acts as a decoy receptor (R) for IL-6/sIL-
6Rα complexes, when present in molar excess.22 We hypothe-
size that sgp130 expression might be a compensatory response 
to limit IL-6 trans-signaling. In line with this, we suggest that 
considerably elevated sgp130 levels in patients with HF may 
reflect markedly enhanced gp130/signal transducer and acti-
vator of transcription 3 signaling in these patients. Although 
gp130-mediated signaling may confer cardioprotective prop-
erties through compensatory hypertrophy, tissue repair, and 
reduced apoptosis,23 continuous and markedly increased 
activation of this signaling, potentially reflected by increased 
sgp130 levels, might have deleterious effects.24 It is conceiv-
able that the nonlinear risk increase seen for sgp130 in the 
present study may reflect a shift from compensatory to det-
rimental gp130-mediated signaling in relation to particularly 
high levels of sgp130.
In contrast to its association with fatal end points, sgp130 
was not associated with the primary end point that included 
contributions from multiple disease mechanisms (ie, HF/
LV remodeling, atherosclerotic/vascular disease, intracranial 
hemorrhage). It is unlikely that the prognostic usefulness of 
sgp130 for all aforementioned disease mechanisms would be 
equally prominent. In fact, experimental studies suggest that 
inhibition of IL-6 trans-signaling could reduce rather than 
enhance atherogenesis.25 The association between sgp130 
levels and atherosclerosis may, therefore, be more complex, 
which again could influence its lack of association with the 
primary end point.
Recent evidence supports targeting of IL-6 signaling as a 
therapeutic strategy for reducing CV disease.10,11 The novel 
fusion protein sgp130Fc, which mimics natural, circulating 
sgp130, selectively inhibits IL-6 trans-signaling.26 We hypoth-
esize that measurements of sgp130 might be used to stratify 
patients most likely to benefit from sgp130Fc therapy, on the 
basis of ongoing, excessive IL-6 trans-signaling. The first 
human phase I study of sgp130Fc in chronic inflammatory 
diseases is scheduled for this year,26 and it is tempting to sug-
gest that similar studies should be performed in chronic HF.
Herein, we demonstrate that sgp130 is associated with 
all-cause and CV mortality and death from WHF also after 
multivariable adjustment. Applying sgp130 concentrations to 
adjusted multivariable models without TnT resulted in signifi-
cant continuous NRIs for all-cause and CV mortality. However, 
sgp130 did not enhance risk prediction in our study popula-
tion when TnT was accounted for. Area under curve analy-
ses favored NT-proBNP as the best single marker for all end 
points and also demonstrated limited isolated discriminatory 
power of sgp130 (Table 3). Still, new biomarkers might offer 
information on pathophysiological processes poorly reflected 
by today’s state-of-the-art biomarkers, despite having lower 
receiver operating characteristics. Although NT-proBNP, and 
potentially also TnT, is a strong predictor of adverse outcome 
in patients with HF, it is unlikely that these biomarkers could 
reflect all pathogenic pathways that are involved in this com-
plex disorder.
The present study examined multiple end points in a large HF 
population with a considerable number of events. However, for 
some subgroup analyses, including the interaction of sgp130 
with rosuvastatin, there were relatively few events, and, there-
fore, these data should be interpreted cautiously. The discrimi-
natory properties of sgp130 alone (Table 3) were limited in our 
population, implying that at present, the clinical usefulness of 
sgp130 is questionable. Also, not all markers (eg, TnT) were 
analyzed in all patients, which may have influenced the power 
of our analyses. In addition, we used a cut point derived from 
an analysis of one end point (all-cause mortality) on all other 
outcomes, which may have influenced the results. However, 
continuous sgp130 performed similarly to this cut point in 
the Cox regression, and the risk of substantially skewing the 
results in favor of all-cause mortality, therefore, seems lim-
ited. Our study was performed in trial patients aged ≥60 years, 
with LV systolic dysfunction and ischemic heart disease and a 
low prevalence of non-CV comorbidity (eg, chronic obstruc-
tive pulmonary disease). Thus, the results may not apply to all 
patients with HF. Also, we could not include an acknowledged 
HF risk model (eg, Seattle HF risk score) in the multivariable 
analyses as we did not have all the requisite variables. Finally, 
there is a need for more standardized methods for measuring 
sgp130, with an established normal range, before it is ready for 
use in clinical practice.
In conclusion, serum sgp130 was associated with fatal out-
comes in patients with chronic systolic HF of ischemic cause, 
but did not seem to predict vascular events, and sgp130 did 
not enhance risk prediction when TnT was accounted for. 
Nonetheless, our findings may suggest a role for sustained 
activation of the gp130/signal transducer and activator of tran-
scription 3 signaling pathway in the pathogenesis of HF, and 
the role of IL-6–related cytokines as a target for therapy in 
HF should be explored further. Furthermore, larger studies 
in more heterogeneous HF populations have to be performed 
before advocating implementation of sgp130 as a biomarker 
in clinical practice.
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CLINICAL PERSPECTIVE
Soluble glycoprotein 130 (sgp130) is a decoy receptor for the central proinflammatory cytokine interleukin-6 (IL-6), a 
marker associated with heart failure (HF) development and myocardial remodeling. IL-6 was also recently causally impli-
cated as a mediator in the pathogenesis of coronary heart disease, and several experimental studies suggest targeting of IL-6 
signaling as a therapeutic strategy for reducing cardiovascular disease. Soluble gp130 has been suggested to reflect the activ-
ity of IL-6–related cytokines. To determine the role of circulating sgp130 in the prediction of fatal and nonfatal outcomes 
in HF, we investigated serum levels of sgp130 in a large contemporary cohort of older patients with systolic HF, receiving 
modern pharmacological therapy, randomly assigned to statin therapy or placebo in a double-blind fashion. Sgp130 inde-
pendently predicted fatal outcomes and improved risk prediction after adjustment for conventional risk markers, as well 
as C-reactive protein, IL-6, and N-terminal pro-B-type natriuretic peptide. However, when also accounting for troponin 
T, sgp130 remained independently predictive of mortality, but no longer provided incremental value in risk assessment as 
assessed by net reclassification improvement scores. In contrast, IL-6 was not associated with any end points after multivari-
able adjustment. Our data support involvement of IL-6 type signaling in chronic HF and suggest that serum sgp130 might 
partly reflect unmodified biological events in HF progression. Measurements of sgp130 might be used in risk stratification 
of patients with HF and possibly also to identify patients most likely to benefit from IL-6 inhibition.
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Supplemental Table I. Baseline differences between total CORONA population and 
sgp130 sub-study. 
CRP and NT-proBNP are displayed as median value (25th-75th percentiles). Other variables are 
shown as number (percentage of total) or as mean (standard deviation) where appropriate.  
Variable 
CORONA  
Total study 
CORONA 
sgp130 sub-study P-value n=5011 n=1452 
Age 72.7 (7.1) 71.8 (6.9) <0.001 
Sex (female) 1180 (23.5) 339 (23.3) 0.888 
NYHA class   0.002 
II 1857 (37.1) 468 (32.2)  
III 3081 (61.5) 967 (66.6)  
IV 73 (1.5) 17 (1.2)  
LVEF (%) 31 (6) 32 (7) <0.001 
BMI (kg/m2) 27.2 (4.5) 27.3 (4.6) 0.657 
SBP (mmHg) 129 (16) 130 (16) 0.526 
DBP (mmHg) 76 (9) 77 (9) 0.002 
Heart rate (b.p.m) 72 (11) 71 (11) 0.017 
Smoking 528 (10.5) 175 (12.1) 0.114 
Medical history    
Prior MI 3006 (60.0) 916 (63.1) <0.001 
Prior PCI or CABG 1229 (24.5) 301 (20.7) <0.001 
Hypertension 3175 (63.4) 1013 (69.8) <0.001 
Diabetes Mellitus 1477 (29.5) 377 (26.0) 0.009 
Stroke 624 (12.5) 173 (11.9) 0.618 
Intermittent Claudication 637 (12.7) 156 (10.7) 0.046 
COPD 109 (2.2) 29 (2.0) 0.757 
Biochemistry    
Total Cholesterol (mmol/L) 5.17 (1.08) 5.23 (1.09) 0.068 
LDL (mmol/L) 3.55 (0.94) 3.64 (0.97) 0.002 
HDL (mmol/L) 1.23 (0.35) 1.23 (0.34) 0.993 
Triglycerides (mmol/L) 2.00 (1.28) 2.01 (1.39) 0.817 
Apo B/Apo A-1 value 0.87 (0.25) 0.89 (0.25) 0.082 
eGFRMDRD (mL/min/1.73 m2) 57.1 (14.4) 57.4 (14.2) 0.458 
NT-proBNP (pmol/L) 173 (73-368) 160 (59-341) 0.032 
CRP (mg/L) 3.5 (1.6-7.5) 3.7 (1.6-7.7) 0.207 
Medication    
Diuretics   <0.001 
None 677 (13.5) 190 (13.1)  
Loop OR Thiazide 3977 (79.4) 1105 (76.1)  
Loop AND Thiazide 357 (7.1) 157 (10.8)  
Aldosterone antagonist 1906 (38.0) 530 (36.5) 0.296 
ACE-inhibitor 3981 (79.4) 1168 (80.4) 0.416 
ARB 637 (12.7) 147 (10.1) 0.008 
Beta blocker 3722 (74.3) 1108 (76.3) 0.123 
Digitalis glycoside 1618 (32.3) 418 (28.8) 0.011 
 
NYHA, New York Heart Association; BMI, body mass index; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; MI, myocardial infarction; PCI, percutaneous coronary 
intervention; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary 
disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ApoB, apolipoprotein B; 
ApoA-1, apolipoprotein A-1; eGFR, estimated glomerular filtration rate; MDRD, modification 
of diet in renal disease; CRP, C-reactive protein; NT-proBNP, amino-terminal pro-brain 
natriuretic peptide; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker. 
Supplemental Table II. Multivariable analyses – effects of continuous sgp130 on 
outcomes. 
log gp130, continuous variable Events HR (95% CI) p-value Wald 
Primary endpoint       
Unadjusted n=1452 411  1.50 (1.08 - 2.08) 0.016 5.78 
Step 1* n=1449 411 1.32 (0.95 - 1.85) 0.100 2.70 
Step 2† n=1434 408 1.32 (0.94 - 1.85) 0.112 2.52 
Step 3‡ n=1196 311  1.25 (0.84 - 1.85) 0.275 1.19 
Step 4§ n=1015 270 0.98 (0.64 - 1.49) 0.912 0.012 
All-cause mortality        
Unadjusted  425 1.91 (1.38 - 2.64) 0.000 15.4 
Step 1  425 1.65 (1.19 - 2.29) 0.003 8.89 
Step 2  422 1.64 (1.17 - 2.29) 0.004 8.27 
Step 3  322 1.75 (1.19 - 2.59) 0.004 8.07 
Step 4  275 1.37 (0.90 - 2.08) 0.146 2.11 
Death from CV cause      
Unadjusted 346  1.77 (1.24 - 2.53) 0.002 9.70 
Step 1 346 1.53 (1.06 - 2.20) 0.023 5.16 
Step 2 344 1.51 (1.04 - 2.19) 0.031 4.67 
Step 3 263  1.52 (0.99 - 2.34) 0.058 3.59 
Step 4 225 1.19 (0.75 - 1.90) 0.466 0.53 
Death from WHF      
Unadjusted 102  3.02 (1.58 - 5.79) 0.001 11.1 
Step 1 102 2.51 (1.28 - 4.90) 0.007 7.21 
Step 2 102 2.51 (1.27 - 4.94) 0.008 7.08 
Step 3 78  3.26 (1.50 - 7.08) 0.003 8.90 
Step 4 69 1.90 (0.83 - 4.37) 0.129 2.30 
Sudden death      
Unadjusted 196 1.33 (0.82 - 2.15) 0.244 1.36 
Step 1 196 1.19 (0.73 - 1.93) 0.489 0.48 
Step 2 194 1.15 (0.70 - 1.90) 0.574 0.32 
Step 3 150 1.09 (0.61 - 1.94) 0.782 0.077 
Step 4 129 1.00 (0.54 - 1.88) 0.991 0.00014 
Coronary endpoint      
Unadjusted 332  1.16 (0.80 - 1.68) 0.425 0.64 
Step 1 332 1.07 (0.74 - 1.56) 0.712 0.14 
Step 2 327 1.01 (0.69 - 1.48) 0.949 0.0041 
Step 3 254  0.89 (0.57 - 1.37) 0.590 0.29 
Step 4 212 0.76 (0.47 - 1.23) 0.265 1.24 
Hospitalization, CV causes      
Unadjusted 613  1.59 (1.22 - 2.08) 0.001 11.4 
Step 1 611 1.47 (1.12 - 1.94) 0.006 7.45 
Step 2 605 1.41 (1.06 - 1.86) 0.017 5.67 
Step 3 491  1.20 (0.87 - 1.64) 0.270 1.22 
Step 4 417 1.07 (0.76 - 1.50) 0.717 0.13 
Hospitalization from WHF      
Unadjusted 330 1.86 (1.29 - 2.68) 0.001 10.9 
Step 1 329 1.67 (1.14 - 2.43) 0.008 7.03 
Step 2 327 1.58 (1.08 - 2.32) 0.018 5.57 
Step 3 268 1.32 (0.85 - 2.05) 0.213 1.55 
Step 4 232 1.19 (0.74 - 1.89) 0.470 0.52 
 
The models are adjusted as follows: *Step 1: LVEF, NYHA functional class, age, body mass 
index, diabetes mellitus, sex, intermittent claudication and heart rate. †Step 2: All variables 
from Step 1 as well as ApoB/Apo A-1 ratio and estimated glomerular filtration rate. ‡Step 3: all 
variables from Step 2 as well as NT-proBNP, IL-6 and CRP. §Step 4: All variables from Step 3 
as well as troponin T. CV, cardiovascular; WHF, worsening heart failure. 
 
Supplemental Table III. Multivariable analyses – effects of extended medical history and medication. 
sgp130, quintiles Primary 
endpoint 
All-cause 
mortality 
Death from 
CV causes 
Death from 
WHF 
Sudden death Coronary 
endpoint 
Hospitalization, 
CV causes 
Hospitalization 
from WHF 
Unadjusted HR 1.29 1.54 1.52 2.27 1.15 1.06 1.21 1.44 
Step 1* 1.19 1.40 1.38 1.98 1.07 1.00 1.14 1.30 
Step 2† 1.22 1.43 1.41 2.00 1.09 0.99 1.12 1.28 
Step 3‡ 1.20 1.51 1.45 2.28 1.17 0.97 1.02 1.17 
Step 4§ 1.12 1.47 1.38 1.85 1.25 0.95 1.00 1.23 
Step 5║          
sgp130 
HR 1.13 1.50 1.42 1.89 1.33 0.97 0.97 1.17 
CI  (0.85 - 1.52) (1.13 - 1.98) (1.04 - 1.94) (1.10 - 3.23) (0.87 - 2.02) (0.68 - 1.37) (0.76 - 1.24) (0.86 - 1.60) 
p-value 0.400 0.004 0.026 0.020 0.182 0.855 0.810 0.323 
Wald 0.71 8.11 4.96 5.37 1.78 0.033 0.058 0.98 
          
Implanted pacemaker 
0.51 0.58 0.52 0.36 0.46 0.55 1.19 1.46 
(0.32 - 0.81) (0.38 - 0.90) (0.31 - 0.85) (0.13 - 1.05) (0.24 - 0.90) (0.33 - 0.91) (0.88 - 1.60) (0.99 - 2.14) 
0.004 0.015 0.010 0.063 0.024 0.021 0.256 0.055 
8.13 5.97 6.68 3.47 5.11 5.31 1.29 3.69 
         
Atrial 
Fibrillation/Flutter 
1.05 1.17 1.14 1.63 0.89 0.96 1.33 1.45 
(0.81 - 1.35) (0.91 - 1.50) (0.86 - 1.50) (0.98 - 2.73) (0.62 - 1.29) (0.72 - 1.28) (1.08 - 1.63) (1.10 - 1.91) 
0.730 0.215 0.359 0.060 0.550 0.767 0.007 0.009 
0.12 1.54 0.84 3.53 0.36 0.088 7.25 6.80 
         
Previous PCI or 
CABG  
0.74 0.76 0.68 0.42 0.85 1.12 1.03 0.86 
(0.53 - 1.04) (0.54 - 1.06) (0.47 - 1.01) (0.17 - 1.04) (0.53 - 1.38) (0.79 - 1.58) (0.80 - 1.32) (0.60 - 1.22) 
0.085 0.100 0.054 0.060 0.516 0.528 0.807 0.400 
2.97 2.70 3.72 3.54 0.42 0.40 0.059 0.71 
         
Hypertension 
1.15 1.04 1.06 0.94 1.31 1.37 1.33 1.51 
(0.86 - 1.54) (0.79 - 1.38) (0.77 - 1.46) (0.53 - 1.68) (0.86 - 2.01) (0.98 - 1.92) (1.05 - 1.68) (1.09 - 2.08) 
0.334 0.776 0.710 0.831 0.214 0.065 0.018 0.012 
0.93 0.081 0.14 0.045 1.55 3.40 5.57 6.27 
         
Previous MI 
1.19 1.13 1.10 1.27 0.86 1.02 1.27 1.45 
(0.91 - 1.57) (0.86 - 1.49) (0.82 - 1.49) (0.73 - 2.19) (0.58 - 1.28) (0.75 - 1.39) (1.02 - 1.58) (1.08 - 1.95) 
0.209 0.368 0.522 0.395 0.451 0.897 0.036 0.015 
1.91 0.95 1.15 0.017 0 0.032 0.13 0.23 
         
COPD 
0.37 0.56 0.46 1.11 0 0.90 1.14 0.79 
(0.09 - 1.51) (0.18 - 1.79) (0.11 - 1.89) (0.25 - 4.99) (0 - 0) (0.28 - 2.89) (0.55 - 2.36) (0.30 - 2.06) 
0.166 0.331 0.284 0.896 0 0.858 0.722 0.628 
1.91 0.95 1.15 0.017 0 0.032 0.13 0.23 
         
Beta-blocker 
1.04 0.87 0.91 0.60 1.37 1.08 1.17 1.25 
(0.75 - 1.43) (0.64 - 1.18) (0.64 - 1.28) (0.33 - 1.08) (0.82 - 2.28) (0.75 - 1.57) (0.91 - 1.51) (0.88 - 1.78) 
0.830 0.378 0.578 0.088 0.234 0.670 0.227 0.219 
0.046 0.78 0.31 2.91 1.42 0.18 1.46 1.51 
         
Aldosterone-
antagonist 
1.29 1.28 1.32 1.95 1.17 1.09 1.05 1.34 
(1.00 - 1.65) (1.00 - 1.63) (1.00 - 1.73) (1.17 - 3.24) (0.81 - 1.67) (0.82 - 1.44) (0.86 - 1.28) (1.03 - 1.75) 
0.047 0.052 0.047 0.010 0.402 0.552 0.637 0.031 
3.95 3.77 3.93 6.64 0.70 0.35 0.22 4.64 
         
ACE-inhibitor 
1.22 1.55 1.46 1.35 1.22 1.19 0.89 0.78 
(0.83 - 1.81) (1.05 - 2.30) (0.95 - 2.24) (0.65 - 2.80) (0.70 - 2.13) (0.76 - 1.87) (0.65 - 1.20) (0.52 - 1.15) 
0.306 0.029 0.086 0.419 0.489 0.438 0.433 0.208 
1.05 4.78 2.95 0.65 0.48 0.60 0.61 1.58 
         
Angiotensin II 
receptor blocker 
0.88 0.99 0.83 1.16 0.72 0.90 0.95 0.75 
(0.50 - 1.53) (0.57 - 1.73) (0.44 - 1.58) (0.39 - 3.43) (0.31 - 1.68) (0.48 - 1.67) (0.64 - 1.42) (0.43 - 1.31) 
0.643 0.979 0.568 0.787 0.453 0.733 0.806 0.313 
0.21 0.00070 0.33 0.073 0.56 0.12 0.060 1.02 
         
Diuretics 
1.14 1.02 1.15 1.22 1.27 0.99 0.97 1.01 
(0.87 - 1.50) (0.77 - 1.33) (0.85 - 1.55) (0.68 - 2.19) (0.86 - 1.86) (0.73 - 1.34) (0.78 - 1.20) (0.76 - 1.35) 
0.338 0.911 0.367 0.502 0.229 0.946 0.783 0.950 
0.92 0.013 0.81 0.45 1.45 0.0046 0.076 0.0039 
         
The models are adjusted as follows: *Step 1(n=1449): LVEF, NYHA functional class, age, body mass index, diabetes mellitus, sex, 
intermittent claudication and heart rate. †Step 2(n=1434): All variables from Step 1 as well as ApoB/Apo A-1 ratio and estimated 
glomerular filtration rate. ‡Step 3(n=1183): All variables from Step 2 as well as NT-proBNP, IL-6 and CRP. §Step 4(n=1015): All 
variables from Step 3 as well as troponin T. ║Step 5(n=1015): All variables from Step 4 as well as extended medical history and 
medications. sgp130, soluble glycoprotein 130; CV, cardiovascular; WHF, worsening heart failure; COPD, chronic obstructive 
pulmonary disease; ACE, angiotensin converting enzyme; PCI, percutaneous coronary intervention; CABG, coronary artery bypass 
grafting; MI, myocardial infarction; HR, hazard ratio; CI, 95% confidence interval.
Supplemental Table IV. Multivariable analyses - Association of IL-6 with outcomes. 
Serum IL-6 (log-transformed, continuous variable) as a predictor of outcomes. All Hazard 
Ratios (HR) are given as HR (95% confidence interval), corresponding p-value. Net 
Reclassification Improvement (NRI); calculated from C-indexes for adjusted models with and 
without inclusion of IL-6, corresponding (p-value). 
Endpoint HR (95% CI) p-value NRI p-value 
Primary endpoint      
Unadjusted n=1452 1.35 (1.23-1.49) <0.001   
Step 1* n=1449 1.28 (1.16-1.41) <0.001   
Step 2† n=1434 1.25 (1.13-1.38) <0.001   
Step 3‡ n=1196 1.02 (0.88-1.19) 0.758 -0.11 0.37 
      
All-cause mortality      
Unadjusted 1.44 (1.32-1.58) <0.001   
Step 1* 1.35 (1.23-1.48) <0.001   
Step 2† 1.34 (1.22-1.47) <0.001   
Step 3‡ 1.11 (0.95-1.28) 0.185 -0.02 0.78 
      
Death from CV cause      
Unadjusted 1.42 (1.28-1.57) <0.001   
Step 1* 1.32 (1.19-1.47) <0.001   
Step 2† 1.30 (1.17-1.45) <0.001   
Step 3‡ 1.05 (0.89-1.24) 0.569 -0.11 0.38 
      
Death from WHF      
Unadjusted 1.62 (1.37-1.93) <0.001   
Step 1* 1.46 (1.22-1.75) <0.001   
Step 2† 1.45 (1.21-1.74) <0.001   
Step 3‡ 1.27 (0.95-1.68) 0.103 -0.03 0.90 
      
Sudden death      
Unadjusted 1.29 (1.12-1.49) <0.001   
Step 1* 1.23 (1.06-1.42) 0.005   
Step 2† 1.21 (1.04-1.40) 0.014   
Step 3‡ 0.91 (0.72-1.15) 0.435 0.15 0.19 
      
Coronary endpoint      
Unadjusted 1.23 (1.10-1.38) <0.001   
Step 1* 1.18 (1.05-1.32) 0.006   
Step 2† 1.14 (1.01-1.28) 0.031   
Step 3‡ 0.95 (0.79-1.13) 0.555 0.08 0.37 
      
Hospitalization, CV causes      
Unadjusted 1.23 (1.13-1.34) <0.001   
Step 1* 1.17 (1.07-1.27) <0.001   
Step 2† 1.15 (1.06-1.26) 0.001   
Step 3‡ 1.07 (0.94-1.21) 0.306 0.02 0.75 
      
Hospitalization from WHF      
Unadjusted 1.40 (1.26-1.55) <0.001   
Step 1* 1.29 (1.16-1.43) <0.001   
Step 2† 1.27 (1.14-1.42) <0.001   
Step 3‡ 1.09 (0.93-1.29) 0.270 0.02 0.85 
The models are adjusted as follows: *Step 1: LVEF, NYHA functional class, age, body mass 
index, diabetes mellitus, sex, intermittent claudication and heart rate. †Step 2: All variables 
from Step 1 as well as ApoB/Apo A-1 ratio and estimated glomerular filtration rate. ‡Step 3: all 
variables from Step 2 as well as NT-proBNP and CRP. CV, cardiovascular; WHF, worsening 
heart failure. 
 
  
Supplemental Table V. Multivariable analyses – effects of sgp130 on variables. 
Fully adjusted multivariable models (Step 4) with extended medical history and medications for 
all-cause mortality, CV mortality and death from WHF, with and without inclusion of fifth 
quintile (Q5) sgp130 concentration. 
Variables 
 All-cause Mortality CV Mortality Death from WHF 
 sgp130  sgp130 sgp130 
 Without With Without With Without With 
Ejection fraction  
(x 100) 
HR 0.99 0.99 0.98 0.98 1.00 1.00 
CI (0.97 - 1.01) (0.97 - 1.01) (0.96 - 1.01) (0.96 - 1.01) (0.96 - 1.05) (0.96 - 1.05) 
p-value 0.219 0.198 0.143 0.135 0.880 0.956 
Wald 1.51 1.66 2.15 2.23 0.02 <0.01 
        
Age (x 10) 
 1.06 1.07 1.05 1.06 1.70 1.73 
 (0.86 - 1.29) (0.87 - 1.31) (0.84 - 1.31) (0.84 - 1.32) (1.10 - 2.62) (1.12 - 2.69) 
 0.597 0.514 0.680 0.628 0.018 0.014 
 0.28 0.43 0.17 0.24 5.62 6.02 
        
Heart rate  
(x 1/10) 
 0.97 0.97 0.94 0.94 1.04 1.05 
 (0.86 - 1.10) (0.86 - 1.10) (0.82 - 1.08) (0.82 - 1.08) (0.82 - 1.33) (0.82 - 1.34) 
 0.681 0.627 0.397 0.359 0.732 0.713 
 0.17 0.24 0.72 0.84 0.12 0.14 
        
Female sex 
 0.89 0.90 0.97 0.98 2.06 1.98 
 (0.63 - 1.25) (0.64 - 1.26) (0.67 - 1.41) (0.67 - 1.41) (1.13 - 3.79) (1.08 - 3.64) 
 0.511 0.529 0.881 0.898 0.019 0.027 
 0.43 0.40 0.02 0.02 5.50 4.91 
        
Diabetes 
Mellitus 
 1.26 1.22 1.19 1.16 1.53 1.43 
 (0.96 - 1.66) (0.93 - 1.61) (0.88 - 1.61) (0.86 - 1.57) (0.90 - 2.59) (0.84 - 2.43) 
 0.093 0.148 0.254 0.337 0.117 0.192 
 2.82 2.09 1.30 0.92 2.46 1.70 
        
Intermittent 
Claudication 
 1.40 1.39 1.28 1.28 1.14 1.18 
 (0.98 - 1.99) (0.97 - 1.99) (0.85 - 1.93) (0.84 - 1.93) (0.48 - 2.73) (0.49 - 2.84) 
 0.068 0.072 0.244 0.249 0.763 0.708 
 3.34 3.23 1.36 1.33 0.091 0.14 
        
BMI 
 0.94 0.94 0.95 0.95 0.96 0.96 
 (0.91 - 0.97) (0.91 - 0.97) (0.91 - 0.98) (0.91 - 0.98) (0.90 - 1.02) (0.90 - 1.02) 
 <0.001 <0.001 0.001 0.001 0.233 0.224 
 13.0 13.0 10.2 10.2 1.42 1.48 
        
NYHA III 
 1.13 1.11 1.10 1.09 1.08 1.06 
 (0.84 - 1.52) (0.83 - 1.50) (0.79 - 1.52) (0.79 - 1.51) (0.58 - 2.02) (0.56 - 2.00) 
 0.411 0.472 0.570 0.601 0.815 0.848 
 0.67 0.52 0.32 0.27 0.06 0.04 
        
NYHA IV 
 1.26 1.40 1.19 1.31 0.76 0.93 
 (0.55 - 2.89) (0.61 - 3.23) (0.48 - 2.94) (0.53 - 3.25) (0.15 - 3.81) (0.18 - 4.72) 
 0.587 0.433 0.704 0.561 0.743 0.929 
 0.29 0.62 0.14 0.34 0.11 <0.01 
        
eGFR  0.99 0.99 0.99 0.99 1.01 1.01 
 (0.98 - 1.00) (0.98 - 1.00) (0.98 - 1.01) (0.98 - 1.00) (0.99 - 1.03) (0.99 - 1.03) 
 0.179 0.109 0.284 0.195 0.213 0.318 
 1.81 2.57 1.15 1.68 1.55 1.00 
        
Apo B/Apo A-1 
ratio 
 1.33 1.35 1.52 1.53 2.20 2.32 
 (0.79 - 2.23) (0.80 - 2.28) (0.86 - 2.67) (0.87 - 2.71) (0.81 - 5.98) (0.84 - 6.38) 
 0.284 0.254 0.149 0.141 0.120 0.103 
 1.15 1.30 2.08 2.16 2.41 2.66 
        
NT-proBNP  
 1.44 1.41 1.53 1.51 1.51 1.47 
 (1.25 - 1.66) (1.23 - 1.63) (1.30 - 1.79) (1.29 - 1.77) (1.14 - 2.02) (1.10 - 1.96) 
 <0.001 <0.001 <0.001 <0.001 0.005 0.009 
 24.7 22.5 27.4 25.6 8.03 6.82 
        
CRP 
 1.15 1.18 1.16 1.18 1.06 1.11 
 (1.01 - 1.31) (1.04 - 1.35) (1.00 - 1.33) (1.02 - 1.36) (0.83 - 1.35) (0.86 - 1.43) 
 0.029 0.013 0.049 0.028 0.645 0.417 
 4.77 6.12 3.86 4.81 0.21 0.66 
        
IL-6 
 1.01 1.00 0.94 0.93 1.21 1.17 
 (0.85 - 1.19) (0.84 - 1.18) (0.78 - 1.14) (0.77 - 1.13) (0.88 - 1.66) (0.85 - 1.61) 
 0.927 0.977 0.557 0.489 0.242 0.337 
 <0.01 <0.01 0.34 0.48 1.37 0.92 
        
TnT 
 1.48 1.46 1.49 1.47 1.76 1.71 
 (1.25 - 1.76) (1.23 - 1.74) (1.23 - 1.80) (1.22 - 1.78) (1.25 - 2.50) (1.20 - 2.43) 
 <0.001 <0.001 <0.001 <0.001 0.001 0.003 
 20.7 18.9 17.3 16.0 10.3 8.84 
        
Pacemaker 
 0.60 0.58 0.52 0.52 0.38 0.36 
 (0.39 - 0.92) (0.38 - 0.90) (0.32 - 0.87) (0.31 - 0.85) (0.13 - 1.10) (0.13 - 1.05) 
 0.018 0.014 0.012 0.010 0.075 0.062 
 5.55 6.00 6.37 6.72 3.18 3.49 
        
Atrial 
fibrillation/flutter 
 1.17 1.16 1.12 1.11 1.50 1.49 
 (0.91 - 1.52) (0.90 - 1.50) (0.84 - 1.49) (0.84 - 1.48) (0.89 - 2.54) (0.88 - 2.52) 
 0.223 0.259 0.439 0.465 0.131 0.135 
 1.48 1.27 0.60 0.53 2.28 2.24 
        
Previous MI 
 1.18 1.14 1.14 1.12 1.45 1.36 
 (0.89 - 1.55) (0.86 - 1.50) (0.84 - 1.54) (0.82 - 1.51) (0.83 - 2.51) (0.78 - 2.36) 
 0.249 0.352 0.401 0.481 0.190 0.283 
 1.33 0.87 0.71 0.50 1.72 1.15 
        
Previous PCI 
 0.76 0.76 0.69 0.69 0.44 0.43 
 (0.54 - 1.06) (0.54 - 1.06) (0.47 - 1.01) (0.47 - 1.01) (0.18 - 1.06) (0.18 - 1.05) 
 0.104 0.102 0.056 0.055 0.067 0.062 
 2.65 2.67 3.66 3.67 3.36 3.47 
        
Hypertension 
 1.05 1.04 1.06 1.06 0.93 0.94 
 (0.79 - 1.39) (0.78 - 1.38) (0.77 - 1.46) (0.77 - 1.45) (0.52 - 1.68) (0.53 - 1.68) 
 0.750 0.786 0.701 0.726 0.820 0.836 
 0.10 0.07 0.15 0.12 0.05 0.04 
        
COPD 
 0.57 0.56 0.47 0.46 1.08 1.02 
 (0.18 - 1.81) (0.18 - 1.79) (0.11 - 1.91) (0.11 - 1.89) (0.24 - 4.95) (0.22 - 4.68) 
 0.341 0.330 0.289 0.282 0.921 0.978 
 0.91 0.95 1.13 1.16 <0.01 <0.01 
        
Digitalis 
glycoside 
 1.09 1.05 1.14 1.11 1.61 1.52 
 (0.84 - 1.41) (0.81 - 1.37) (0.86 - 1.52) (0.83 - 1.49) (0.96 - 2.71) (0.91 - 2.57) 
 0.541 0.701 0.364 0.468 0.069 0.113 
 0.37 0.15 0.82 0.53 3.31 2.52 
        
ACE-inhibitor 
 1.51 1.55 1.41 1.45 1.22 1.35 
 (1.01 - 2.24) (1.04 - 2.30) (0.92 - 2.17) (0.94 - 2.24) (0.58 - 2.54) (0.64 - 2.82) 
 0.043 0.030 0.119 0.089 0.600 0.429 
 4.10 4.73 2.43 2.89 0.27 0.62 
        
Angiotension II 
receptor blocker 
 1.00 0.99 0.83 0.82 1.08 1.10 
 (0.57 - 1.75) (0.57 - 1.72) (0.43 - 1.58) (0.43 - 1.56) (0.36 - 3.23) (0.37 - 3.28) 
 0.990 0.966 0.570 0.549 0.898 0.869 
 <0.01 <0.01 0.32 0.36 0.02 0.03 
        
Beta-blocker 
 0.86 0.87 0.90 0.91 0.63 0.62 
 (0.64 - 1.17) (0.64 - 1.19) (0.64 - 1.28) (0.64 - 1.29) (0.34 - 1.15) (0.34 - 1.12) 
 0.346 0.384 0.573 0.594 0.129 0.111 
 0.89 0.76 0.32 0.28 2.30 2.54 
        
Aldosterone 
antagonist 
 1.28 1.27 1.31 1.30 1.85 1.87 
 (1.00 - 1.64) (0.99 - 1.63) (1.00 - 1.73) (0.99 - 1.71) (1.11 - 3.08) (1.12 - 3.12) 
 0.051 0.060 0.052 0.060 0.018 0.016 
 3.81 3.55 3.77 3.55 5.58 5.77 
        
Diuretics 
 1.02 1.01 1.14 1.13 1.17 1.14 
 (0.77 - 1.34) (0.77 - 1.33) (0.84 - 1.55) (0.84 - 1.54) (0.64 - 2.14) (0.63 - 2.07) 
 0.899 0.945 0.388 0.416 0.601 0.672 
 0.02 <0.01 0.75 0.66 0.27 0.18 
        
Q5 sgp130 
  1.49  1.41  1.80 
  (1.13 - 1.97)  (1.03 - 1.92)  (1.05 - 3.10) 
  0.005  0.031  0.033 
  7.86  4.64  4.52 
 
HR, Hazard ratio; CI, 95% Confidence interval for HR; Wald, Wald score; BMI, Body mass 
index; NYHA, New York Heart Association functional class; eGFR, estimated glomerular 
filtration rate; Apo B, apolipoprotein B; Apo A-1, apolipoprotein A-1; NT-proBNP, log-
transformed amino-terminal pro B-type natriuretic peptide; CRP, log-transformed C-reactive 
protein; IL-6, log-transformed interleukin 6; TnT, log-transformed troponin T; MI, myocardial 
infarction; PCI, percutaneous coronary intervention; COPD, chronic obstructive pulmonary 
disease; ACE, angiotensin converting enzyme; Q5 sgp130, fifth quintile soluble glycoprotein 
130 concentration. 
  
Supplemental Table VI. Multivariable analyses – effects of sgp130 on outcomes in placebo 
arm of sub-study.  
sgp130, quintiles Events HR  (95% CI) p-value Wald 
Primary endpoint       
Unadjusted n=720 214 1.15 (0.82 - 1.62) 0.404 0.70 
Step 1* n=719 214  1.07 (0.76 - 1.51) 0.697 0.15 
Step 2† n=712 212  1.07 (0.76 - 1.51) 0.697 0.15 
Step 3‡ n=586 162 1.17 (0.78 - 1.73) 0.451 0.57 
Step 4§ n=508 143 1.17 (0.77 - 1.78) 0.459 0.55 
All-cause mortality        
Unadjusted  223 1.46 (1.07 - 1.99) 0.019 5.55 
Step 1  223 1.32 (0.96 - 1.82) 0.086 2.96 
Step 2  220 1.33 (0.96 - 1.84) 0.082 3.02 
Step 3  167 1.57 (1.08 - 2.27) 0.018 5.62 
Step 4  143 1.64 (1.11 - 2.44) 0.014 6.05 
Death from CV cause      
Unadjusted 178 1.32 (0.92 - 1.89) 0.129 2.31 
Step 1 178 1.20 (0.83 - 1.73) 0.338 0.92 
Step 2 176  1.21 (0.83 - 1.75) 0.320 0.99 
Step 3 134  1.38 (0.90 - 2.11) 0.141 2.16 
Step 4 117 1.51 (0.97 - 2.37) 0.071 3.26 
Death from WHF      
Unadjusted 55  2.17 (1.23 - 3.85) 0.008 7.06 
Step 1 55  1.87 (1.04 - 3.39) 0.038 4.31 
Step 2 55  1.84 (1.01 - 3.36) 0.046 3.99 
Step 3 41  2.86 (1.41 - 5.80) 0.004 8.47 
Step 4 37 2.71 (1.31 - 5.59) 0.007 7.26 
Sudden death      
Unadjusted 102 0.84 (0.48 - 1.45) 0.529 0.40 
Step 1 102 0.76 (0.44 - 1.33) 0.340 0.91 
Step 2 100 0.79 (0.45 - 1.37) 0.397 0.72 
Step 3 77 0.87 (0.47 - 1.62) 0.661 0.19 
Step 4 67 1.06 (0.55 - 2.04) 0.864 0.029 
Coronary endpoint      
Unadjusted 164 0.76 (0.49 - 1.19) 0.233 1.42 
Step 1 164 0.71 (0.45 - 1.11) 0.130 2.30 
Step 2 161  0.73 (0.47 - 1.14) 0.168 1.90 
Step 3 126  0.80 (0.48 - 1.33) 0.389 0.74 
Step 4 108 0.68 (0.38 - 1.21) 0.192 1.71 
Hospitalization, CV causes      
Unadjusted 310  1.14 (0.86 - 1.52) 0.348 0.88 
Step 1 309 1.04 (0.78 - 1.38) 0.812 0.056 
Step 2 305 1.04 (0.78 - 1.39) 0.797 0.066 
Step 3 245  1.08 (0.78 - 1.49) 0.650 0.21 
Step 4 213 1.04 (0.73 - 1.47) 0.837 0.042 
Hospitalization from WHF      
Unadjusted 167 1.54 (1.08 - 2.20) 0.017 5.65 
Step 1 167  1.32 (0.92 - 1.89) 0.138 2.20 
Step 2 166 1.32 (0.91 - 1.90) 0.139 2.19 
Step 3 135 1.59 (1.06 - 2.38) 0.024 5.07 
Step 4 118 1.61 (1.04 - 2.47) 0.031 4.64 
 
The models are adjusted as follows: *Step 1: LVEF, NYHA functional class, age, body mass 
index, diabetes mellitus, sex, intermittent claudication and heart rate. †Step 2: All variables 
from Step 1 as well as ApoB/Apo A-1 ratio and estimated glomerular filtration rate. ‡Step 3: all 
variables from Step 2 as well as NT-proBNP, IL-6 and CRP. §Step 4: All variables from Step 3 
as well as troponin T. CV, cardiovascular; WHF, worsening heart failure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure Legends 
Supplemental Figure.  
Patient selection for sub-study analyses. The total CORONA population consisted of 5011 
patients, in which NT-proBNP and CRP was measured in 3664 and 4961 patients respectively. 
The predefined cytokine sub-study consisted of 1480 patients. Due to limited plasma/serum, all 
parameters could not be analyzed in all patients. The number of patients with sgp130, NT-
proBNP, IL-6, CRP and TnT measurements was 1015. 
 
 
 
 
 
 
 
  
Supplemental Figure. 
 
 
 
